FutureMeds Enhances Leadership Structure to Support Growth, and Meet Evolving Sponsor, CRO and Partner Demand

As FutureMeds enters the next phase of growth, the organisation is deliberately evolving its leadership structure to protect the operational DNA that underpins site performance and patient access, while strengthening the capabilities required for sustained, scalable value creation. 

FutureMeds has introduced a series of executive leadership appointments aimed at reinforcing delivery reliability, financial discipline and structured growth, as the clinical trial environment becomes increasingly operationally complex and performance-driven. 

The appointments include Marcin Gondek as Chief Operating Officer, Paul Maddison as Chief Financial Officer, and Iwona Tongbhoyai as Chief Growth Officer.  

The announcement follows the recent appointment of Nachiket Chandak as Chief Commercial Officer to support the dedicated clinical research organisation’s commercial development and client partnerships.

“To achieve this vision, we consistently seek exceptional talent who are committed to overcoming complex challenges and advancing clinical research in a thoughtful and disciplined way to help drive the organisation forward. The time has come to strengthen our Executive Team, and I am proud to see this leadership group come together at a pivotal stage of our growth. The future of clinical research is being shaped now, and we are committed to playing a responsible and forward-looking role in that evolution.” 

— Dr Radoslaw Janiak, Chief Executive Officer 

Together, the changes reflect a deliberate evolution of the company’s leadership architecture to match expanding geographic scope, therapeutic breadth and decentralised service model, while maintaining a high level of consistency in site performance and patient access. 

Operational leadership aligned with execution and site performance 

Marcin Gondek, co-founder, has been appointed Chief Operating Officer, transitioning from his previous role as Chief Financial Officer.  

A graduate in Economics from the University of Wrocław, he brings more than a decade of senior leadership experience across finance, IT, site operations, project managment and contracting within multinational clinical research organisations, including Synexus, where he led finance across Europe and supported the integration of European and US businesses. 

The transition reflects the organisation’s emphasis on cross-functional operational oversight, particularly as Sponsors and CROs increasingly prioritise predictable delivery, recruitment performance and operational readiness across site networks. 

His priorities will focus on aligning patient engagement processes through digitalisation and automation, supporting site development across the network and coordinating expansion in countries with an existing presence. 

“Sustained performance in a dedicated site network like ours relies on strong, autonomous local teams supported by clear and aligned operational frameworks. As we expand our capabilities and open additional sites across Europe, my focus is on strengthening the processes and systems that enable our sites to operate more effectively while delivering on our commitments to Sponsors and CROs, with the ultimate goal of accelerating patient access to new therapies worldwide.” 

— Marcin Gondek, Chief Operating Officer at FutureMeds  

Financial leadership to drive rapid and sustainable growth 

Paul Maddison has been appointed Chief Financial Officer, bringing extensive experience of financial leadership and M&A in fast-growing, international private businesses from his roles with INEOS, Deloitte and KPMG over the past 25 years. 

Paul has over 10 years of healthcare and life sciences sector experience, including M&A advisory work with Synexus Clinical Research, Signature Discovery, Philips Healthcare, Advanced Medical Solutions, Scapa, Dechra Pharmaceuticals, as well as financial advisory to over 40 NHS organisations supporting service transformation. 

In his role, Paul will prioritise process automation and financial infrastructure to support site acquisitions and operational growth, areas that directly influence transparency and efficiency for Sponsors and CRO partners. 

“FutureMeds has built a strong financial foundation over recent years, and my role is to build on and accelerate that work as the organisation continues to scale. Our focus is on strengthening automation, enhancing process clarity and supporting disciplined growth in a way that remains closely aligned with operational delivery, site performance and the expectations of our clients and partners.”   

— Paul Maddison, Chief Financial Officer 

Growth leadership focused on partnerships, therapeutic depth and access 

Iwona Tongbhoyai has been appointed Chief Growth Officer, transitioning from her previous role as Chief Client Solutions Officer.  

With over 18 years of experience in site and clinical trials management and more than seven years in consultancy, she has led initiatives spanning global start-up readiness, transformation projects, M&As, strategic planning and decentralised trial delivery. 

Her expanded remit includes geographic and operational expansion, therapeutic area development in oncology and CNS, new service line development to provide impactful solutions to clients, and continued growth of FutureMeds @home’s services, particularly in rare disease trials where patient access remains a key constraint. 

“Sustained value creation in clinical research increasingly depends on access, geographic reach, operational excellence, and meaningful patient-centric solutions. By expanding our geographical reach, strengthening our decentralised capabilities, deepening strategic alliances, and sharpening our therapeutic focus, we aim to enable more inclusive, reliable, and efficient trial delivery, while remaining closely aligned with operational realities and the evolving needs of our clients.” 

— Iwona Tongbhoyai, Chief Growth Officer 

Leadership continuity and commercial alignment 

The appointments build on the organisation’s recent leadership evolution, including the appointment of Nachiket Chandak as Chief Commercial Officer. Having joined the company as Senior Business Development Director two years ago, Nach has played a central role in strengthening Sponsor and CRO engagement and supporting strategic growth initiatives. 

The combined leadership structure is intended to align commercial strategy, operational execution and financial governance more closely as the organisation scales. 

Hard-wiring the organisation for value creation

The leadership changes are designed to hard-wire the engine for value creation and delivery harmonisation across Europe by elevating internal domain experts and introducing specialist financial leadership, while maintaining a lean, execution-focused executive structure. 

This approach is intended to: 

• Maintain service reliability during expansion 

• Increase operational alignment across sites and support teams 

• Strengthen predictability in delivery for Sponsors and CROs 

• Support patient access through more efficient recruitment and operational workflows 

  
  

“We are investing in the leadership required to help our clients, teams and patients progress in a complex and evolving research environment,” added Radoslaw Janiak, Chief Executive Officer.  

“By elevating proven internal leaders and adding targeted expertise, we are strengthening our ability to scale responsibly, protect delivery standards and remain a reliable partner to Sponsors and CROs without overloading the organisation’s structure.” 

As clinical trials continue to demand greater operational coordination, patient-centric recruitment strategies and geographically diverse site capabilities, FutureMeds' leadership evolution is intended to protect what has historically differentiated the organisation: consistent execution, strong site performance and a model designed to scale without compromising quality.